Search Result

Results for "

Idiopathic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Angiotensin Receptor (4) Apical Sodium-Dependent Bile Acid Transporter (2) Apoptosis (4) Bacterial (3) Btk (1) c-Kit (1) Calcium Channel (1) CD38 (1) Chloride Channel (2) Dipeptidyl Peptidase (1) Drug Metabolite (3) EGFR (1) Endothelin Receptor (3) Ephrin Receptor (1) Guanylate Cyclase (2) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (13) Interleukin Related (1) Isotope-Labeled Compounds (5) JAK (2) JNK (1) LPL Receptor (3) mAChR (1) MMP (2) mTOR (2) PDGFR (1) Phosphodiesterase (PDE) (5) PI3K (3) Proteasome (1) RET (1) STAT (1) TGF-β Receptor (2) TNF Receptor (2)
By Research Areas:	Cancer (10) Cardiovascular Disease (9) Endocrinology (8) Infection (1) Inflammation/Immunology (38) Metabolic Disease (7) Neurological Disease (2)

By Targets:

5-HT Receptor (1)

Angiotensin Receptor (4)

Apical Sodium-Dependent Bile Acid Transporter (2)

Apoptosis (4)

Bacterial (3)

Btk (1)

c-Kit (1)

Calcium Channel (1)

CD38 (1)

Chloride Channel (2)

Dipeptidyl Peptidase (1)

Drug Metabolite (3)

EGFR (1)

Endothelin Receptor (3)

Ephrin Receptor (1)

Guanylate Cyclase (2)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (13)

Interleukin Related (1)

Isotope-Labeled Compounds (5)

JAK (2)

JNK (1)

LPL Receptor (3)

mAChR (1)

MMP (2)

mTOR (2)

PDGFR (1)

Phosphodiesterase (PDE) (5)

PI3K (3)

Proteasome (1)

RET (1)

STAT (1)

TGF-β Receptor (2)

TNF Receptor (2)

By Research Areas:

Cancer (10)

Cardiovascular Disease (9)

Endocrinology (8)

Infection (1)

Inflammation/Immunology (38)

Metabolic Disease (7)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139310

GLPG2938

LPL Receptor Others

GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis .

GLPG2938	LPL Receptor	Others
GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis .

HY-B0674

Ebastine 2 Publications Verification LAS-W 090; RP64305	Histamine Receptor	Inflammation/Immunology Endocrinology
Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research .

HY-B0801A

Fexofenadine hydrochloride 3 Publications Verification MDL-16455 hydrochloride; Terfenadine carboxylate hydrochloride	Histamine Receptor	Inflammation/Immunology
Fexofenadine (MDL-16455) hydrochloride is an orally active and nonsedative H₁ receptor antagonist. Fexofenadine hydrochloride can be used in allergic rhinitis and chronic idiopathic urticarial research .

HY-135088

Autotaxin-IN-4	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis .

HY-100657

meta-Fexofenadine meta-MDL-16455; meta-Terfenadine carboxylate	Drug Metabolite	Inflammation/Immunology
meta-Fexofenadine (meta-MDL-16455) is an impurity of Fexofenadine . Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial .

HY-B0801

Fexofenadine 3 Publications Verification MDL-16455; Terfenadine carboxylate	Histamine Receptor	Inflammation/Immunology
Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research .

HY-147741

DPPY	JAK Btk EGFR	Inflammation/Immunology Cancer
DPPY (compound 6) is a potent PTK inhibitor with IC₅₀ values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

HY-P99288

FG-3019 Pamrevlumab; Anti-Human CTGF Recombinant Antibody	Apoptosis	Cancer
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .

HY-151955

TGFβ1-IN-3	TGF-β Receptor	Inflammation/Immunology
TGFβ1-IN-3 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-3 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-151954

TGFβ1-IN-2	TGF-β Receptor	Inflammation/Immunology
TGFβ1-IN-2 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-2 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-117873

KBP-7018	c-Kit RET PDGFR	Infection
KBP-7018 is a tyrosine kinase-selective inhibitor. KBP-7018 has potent inhibitory effects on c-KIT, PDGFR, and RET with IC₅₀ values of 10 nM, 7.6 nM and 25 nM, respectively. KBP-7018 can be used for the research of idiopathic pulmonary fibrosis .

HY-14184

Macitentan Maximum Cited Publications 8 Publications Verification ACT-064992	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-151976

STAT3-IN-15 1 Publications Verification	STAT	Inflammation/Immunology
STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .

HY-100619A

BMS-986020 sodium 4 Publications Verification AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .

HY-100619

BMS-986020 4 Publications Verification AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-B0944

Pidotimod	Bacterial	Inflammation/Immunology
Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .

HY-14184S

Macitentan-d4 ACT-064992-d₄	Isotope-Labeled Compounds Endothelin Receptor Apoptosis	Cardiovascular Disease
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-138304

CC-90001 1 Publications Verification	JNK	Inflammation/Immunology
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .

HY-B0164

Mizolastine	Histamine Receptor	Inflammation/Immunology
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-B0164A

Mizolastine dihydrochloride	Histamine Receptor	Inflammation/Immunology
Mizolastine dihydrochloride is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine dihydrochloride effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine dihydrochloride can be used in studies of allergic rhinitis and chronic idiopathic urticarial .

HY-156297

β5i-IN-1	Proteasome	Inflammation/Immunology
β5i-IN-1 is a potent and selective inhibitor of β5i with a IC₅₀ of 8.463 nM. β5i-IN-1 releases TNF-α and IL-6 and influences the transcriptional activity of NF-κB. β5i-IN-1 can be used in study idiopathic pulmonary fibrosis .

HY-147742

Thi-DPPY	JAK	Inflammation/Immunology
Thi-DPPY (compound 8e) is a potent and orally active JAK3 inhibitor with IC₅₀ values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

HY-144743

ATX inhibitor 12	Phosphodiesterase (PDE)	Others
ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC₅₀ of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .

HY-147946

PDE1-IN-4	Phosphodiesterase (PDE) Calcium Channel	Inflammation/Immunology
PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC₅₀ values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-B0679

Lubiprostone 1 Publications Verification RU-0211; SPI-0211	Chloride Channel	Metabolic Disease
Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.

HY-131274

Fexofenadine Impurity F	Drug Metabolite	Others
Fexofenadine Impurity F is the impurity of Fexofenadine. Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial .

HY-135089

Autotaxin-IN-5	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-5 (compound 63), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-5 has the potential to treat idiopathic pulmonary fibrosis .

HY-116617

15-Keto Travoprost 15-Keto Fluprostenol isopropyl ester	Drug Metabolite	Others
15-Keto Travoprost (15-Keto Fluprostenol isopropyl ester) is a metabolite of Travoprost (HY-B0584). 15-Keto Travoprost shows stimulatory effect on the growth and thickening of the eyelashes .

HY-B0679S

Lubiprostone-d7 RU-0211-d₇; SPI-0211-d₇	Chloride Channel	Metabolic Disease
Lubiprostone-d₇ (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].

HY-14184A

Macitentan (n-butyl analogue)	Endothelin Receptor	Cardiovascular Disease Endocrinology
Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

HY-P99466

Begelomab SAND-26	Dipeptidyl Peptidase	Inflammation/Immunology
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .

HY-B0801AS

Fexofenadine-d10 hydrochloride MDL-16455-d₁₀ hydrochloride; Terfenadine carboxylate-d₁₀ hydrochloride	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology Endocrinology
Fexofenadine-d₁₀ (hydrochloride) is deuterium labeled Fexofenadine (hydrochloride). Fexofenadine hydrochloride (MDL-16455 hydrochloride), a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years)[1].

HY-135053

Autotaxin-IN-3

Phosphodiesterase (PDE) Inflammation/Immunology

Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC₅₀ of 2.4 nM, compound 33, sourced from patent WO2018212534A1 .

Autotaxin-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC₅₀ of 2.4 nM, compound 33, sourced from patent WO2018212534A1 .

HY-B0674S

Ebastine-d5	Histamine Receptor	Inflammation/Immunology Endocrinology
Ebastine-d₅ is the deuterium labeled Ebastine. Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research[1][2].

HY-B0801S2

Fexofenadine-d3 MDL-16455-d₃; Terfenadine carboxylate-d₃	Histamine Receptor	Inflammation/Immunology
Fexofenadine-d₃ is the deuterium labeled Fexofenadine[1]. Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[2][3][4].

HY-B0801AR

Fexofenadine hydrochloride (Standard) MDL-16455 hydrochloride (Standard); Terfenadine carboxylate hydrochloride (Standard)	Histamine Receptor	Inflammation/Immunology
Fexofenadine (hydrochloride) (Standard) is the analytical standard of Fexofenadine (hydrochloride). This product is intended for research and analytical applications. Fexofenadine (MDL-16455) hydrochloride is an orally active and nonsedative H₁ receptor antagonist. Fexofenadine hydrochloride can be used in allergic rhinitis and chronic idiopathic urticarial research .

HY-145358

FAP-PI3KI1	PI3K	Cancer
FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition .

HY-100657S

Meta-Fexofenadine-d6 meta-MDL-16455-d₆; meta-Terfenadine carboxylate-d₆	Isotope-Labeled Compounds	Inflammation/Immunology
Meta-Fexofenadine-d₆ is the deuterium labeled meta-Fexofenadine. meta-Fexofenadine (meta-MDL-16455) is an impurity of Fexofenadine[1]. Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial[2].

HY-15790A

Elobixibat hydrate A 3309 hydrate; AZD 7806 hydrate	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC₅₀ values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research .

HY-147936

TP0556351	MMP	Inflammation/Immunology
TP0556351 is a potent and selective matrix metalloproteinase-2 (MMP2) inhibitor with an IC₅₀ value of 0.2 nM. TP0556351 reduces the amount of collagen in the lungs of a Bleomycin-induced pulmonary fibrosis mouse model. TP0556351 can be used for researching idiopathic pulmonary fibrosis (IPF) .

HY-B0814

Levocetirizine (R)-Cetirizine
Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-W010841

Levocetirizine dihydrochloride (R)-Cetirizine dihydrochloride	Histamine Receptor	Inflammation/Immunology Endocrinology
Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-108847

Etanercept 4 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P99730

Mezagitamab TAK-079	CD38	Cancer
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

HY-B0814S

Levocetirizine-d4 dihydrochloride (R)-Cetirizine-d₄(dihydrochloride)	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology Endocrinology
Levocetirizine-d₄ (dihydrochloride) is the deuterium labeled Levocetirizine. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

HY-P1839

Angiotensin I/II (1-5)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

Cat. No.	Product Name	Target	Research Area

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .

HY-P1839A

Angiotensin I/II (1-5) (TFA)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-108741

Plecanatide	Guanylate Cyclase	Inflammation/Immunology
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .

HY-P1839

Angiotensin I/II (1-5)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-P1829

Angiotensin I/II (1-6)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-P1829A

Angiotensin I/II (1-6) (TFA)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

Cat. No.	Product Name	Target	Research Area

HY-P99288

FG-3019 Pamrevlumab; Anti-Human CTGF Recombinant Antibody	Apoptosis	Cancer
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-P99466

Begelomab SAND-26	Dipeptidyl Peptidase	Inflammation/Immunology
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .

HY-108847

Etanercept 4 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P99477

Bevifimod PRTX-100	Inhibitory Antibodies	Cardiovascular Disease Inflammation/Immunology
Bevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research .

HY-P99730

Mezagitamab TAK-079	CD38	Cancer
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

Cat. No.	Product Name	Chemical Structure

HY-14184S

Macitentan-d4
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-B0679S

Lubiprostone-d7
Lubiprostone-d₇ (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].

HY-B0801AS

Fexofenadine-d10 hydrochloride
Fexofenadine-d₁₀ (hydrochloride) is deuterium labeled Fexofenadine (hydrochloride). Fexofenadine hydrochloride (MDL-16455 hydrochloride), a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial (person aged ≥16 years)[1].

HY-B0674S

Ebastine-d5
Ebastine-d₅ is the deuterium labeled Ebastine. Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research[1][2].

HY-B0801S2

Fexofenadine-d3
Fexofenadine-d₃ is the deuterium labeled Fexofenadine[1]. Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[2][3][4].

HY-100657S

Meta-Fexofenadine-d6
Meta-Fexofenadine-d₆ is the deuterium labeled meta-Fexofenadine. meta-Fexofenadine (meta-MDL-16455) is an impurity of Fexofenadine[1]. Fexofenadine, a H1R antagonist, is an anti-allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial[2].

HY-B0814S

Levocetirizine-d4 dihydrochloride

Levocetirizine-d₄ (dihydrochloride) is the deuterium labeled Levocetirizine. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

HY-B0814S1

Levocetirizine-d4

Levocetirizine-d₄ ((R)-Cetirizine-d₄) is the deuterium-labeled Levocetirizine (HY-B0814) . Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: